4AB Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$128.20 |
| 52 Week High | US$128.20 |
| 52 Week Low | US$128.20 |
| Beta | 0.47 |
| 1 Month Change | 0% |
| 3 Month Change | -0.35% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4AB | BG Biotechs | BG Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how 4AB performed against the BG Biotechs industry.
Return vs Market: Insufficient data to determine how 4AB performed against the BG Market.
Price Volatility
| 4AB volatility | |
|---|---|
| 4AB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in BG Market | 0% |
| 10% least volatile stocks in BG Market | 0% |
Stable Share Price: 4AB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4AB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine.
AbbVie Inc. Fundamentals Summary
| 4AB fundamental statistics | |
|---|---|
| Market cap | €239.57b |
| Earnings (TTM) | €8.10b |
| Revenue (TTM) | €52.54b |
29.6x
P/E Ratio4.6x
P/S RatioIs 4AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4AB income statement (TTM) | |
|---|---|
| Revenue | US$56.02b |
| Cost of Revenue | US$16.54b |
| Gross Profit | US$39.48b |
| Other Expenses | US$30.85b |
| Earnings | US$8.64b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 27, 2023
| Earnings per share (EPS) | 4.89 |
| Gross Margin | 70.47% |
| Net Profit Margin | 15.41% |
| Debt/Equity Ratio | 476.0% |
How did 4AB perform over the long term?
See historical performance and comparison